-----

#### TRIHEXYPHENIDYL HYDROCHLORIDE TABLETS, USP


### **Rx only**

### DESCRIPTION

Trihexyphenidyl HCl is a synthetic antispasmodic. Each tablet for oral administration, contains 2 mg or 5 mg trihexyphenidyl HCl, each strength also containing as inactive ingredients: magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.

Trihexyphenidyl HCl is a white or slightly off white, crystalline powder, having not more than a very faint odor.

Trihexyphenidyl HCl is the substituted piperidine salt, 1-piperidinepropanol, $\alpha$ -cyclohexyl- $\alpha$ -phenyl-,hydrochloride,(±)-. The structural formula is:



C<sub>20</sub>H<sub>31</sub>NO•HCI

M.W. = 337.93

## CLINICAL PHARMACOLOGY

Trihexyphenidyl exerts a direct inhibitory effect upon the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly upon the muscle tissue itself and indirectly through an inhibitory effect upon the parasympathetic nervous system. Its therapeutic properties are similar to those of atropine, although undesirable side effects are ordinarily less frequent and severe than with the latter.

#### INDICATIONS AND USAGE

Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.

#### WARNINGS

Patients to be treated with trihexyphenidyl HCl should have a gonioscope evaluation and close monitoring of intraocular pressures at regular periodic intervals.

## PRECAUTIONS

Although trihexyphenidyl HCl is *not* contraindicated for patients with cardiac, liver, or kidney disorders, or with hypertension, such patients should be maintained under close observation.

Since the use of trihexyphenidyl HCl may, in some cases, continue indefinitely and since it has atropinelike properties, patients should be subjected to constant and careful long-term observation to avoid allergic and other untoward reactions. Inasmuch as trihexyphenidyl HCl possesses some parasympatholytic activity, it should be used with caution in patients with glaucoma, obstructive disease of the gastrointestinal or genitourinary tracts, and in elderly males with possible prostatic hypertrophy. Geriatric patients, particularly over the age of 60, frequently develop increased sensitivity to the actions of drugs of this type, and hence, require strict dosage regulation. Incipient glaucoma may be precipitated by parasympatholytic drugs such as trihexyphenidyl HCl.

Tardive dyskinesia may appear in some patients on long-term therapy with antipsychotic drugs or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia and, in some instances, may aggravate them. However, parkinsonism and tardive dyskinesia often coexist in patients receiving chronic neuroleptic treatment, and anticholinergic therapy with trihexyphenidyl HCl may relieve some of these parkinsonism symptoms.

## **ADVERSE REACTIONS**

Minor side effects, such as dryness of the mouth, blurring of vision, dizziness, mild nausea or nervousness, will be experienced by 30 to 50 percent of all patients. These sensations, however, are much less troublesome with trihexyphenidyl HCl than with belladonna alkaloids and are usually less disturbing than unalleviated parkinsonism. Such reactions tend to become less pronounced, and even to disappear, as treatment continues. Even before these reactions have remitted spontaneously, they may often be controlled by careful adjustment of dosage form, amount of drug, or interval between doses.

Isolated instances of suppurative parotitis secondary to excessive dryness at the mouth, skin rashes, dilatation of the colon, paralytic ileus, and certain psychiatric manifestations such as delusions and hallucinations, plus one doubtful case of paranoia all of which may occur with any of the atropine-like drugs, have been reported rarely with trihexyphenidyl hydrochloride.

Patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. Such patients should be allowed to develop a tolerance through the initial administration of a small dose and gradual increase in dose until an effective level is reached. If a severe reaction should occur, administration of the drug should be discontinued for a few days and then resumed at a lower dosage. Psychiatric disturbances can result from indiscriminate use (leading to overdosage) to sustain continued euphoria.

Potential side effects associated with the use of any atropine-like drugs include constipation, drowsiness, urinary hesitancy or retention, tachycardia, dilation of the pupil, increased intraocular tension, weakness, vomiting, and headache.

The occurrence of angle-closure glaucoma due to long-term treatment with trihexyphenidyl has been reported.

## DOSAGE AND ADMINISTRATION

Dosage should be individualized. The initial dose should be low and then increased gradually, especially in patients over 60 years of age. Whether trihexyphenidyl HCl may best be given before or after meals should be determined by the way the patient reacts. Postencephalitic patients, who are

usually more prone to excessive salivation, may prefer to take it after meals and may, in addition, require small amounts of atropine which, under such circumstances, is sometimes an effective adjuvant. If trihexyphenidyl HCl tends to dry the mouth excessively, it may be better to take it before meals, unless it causes nausea. If taken after meals, the thirst sometimes induced can be allayed by mint candies, chewing gum or water.

## Trihexyphenidyl HCl in Idiopathic Parkinsonism

As initial therapy for parkinsonism, 1 mg of trihexyphenidyl in tablet form may be administered the first day. The dose may then be increased by 2 mg increments at intervals of three to five days, until a total of 6 to 10 mg is given daily. The total daily dose will depend upon what is found to be the optimal level. Many patients derive maximum benefit from this daily total of 6 to 10 mg, but some patients, chiefly those in the postencephalitic group, may require a total daily dose of 12 to 15 mg.

## Trihexyphenidyl HCl in Drug-Induced Parkinsonism

The size and frequency of dose of trihexyphenidyl HCl needed to control extrapyramidal reactions to commonly employed tranquilizers, notably the phenothiazines, thioxanthenes, and butyrophenones, must be determined empirically. The total daily dosage usually ranges between 5 and 15 mg, although, in some cases, these reactions have been satisfactorily controlled on as little as 1 mg daily. It may be advisable to commence therapy with a single 1 mg dose. If the extrapyramidal manifestations are not controlled in a few hours, the subsequent doses may be progressively increased until satisfactory control is achieved. Satisfactory control may sometimes be more rapidly achieved by temporarily reducing the dosage of the tranquilizer on instituting trihexyphenidyl HCl therapy and then adjusting dosage of both drugs until the desired ataractic effect is retained without onset of extrapyramidal reactions.

It is sometimes possible to maintain the patient on a reduced trihexyphenidyl HCl dosage after the reactions have remained under control for several days. Instances have been reported in which these reactions have remained in remission for long periods after trihexyphenidyl HCl therapy was discontinued.

# Concomitant Use of Trihexyphenidyl HCl with Levodopa

When trihexyphenidyl HCl is used concomitantly with levodopa, the usual dose of each may need to be reduced. Careful adjustment is necessary, depending on side effects and degree of symptom control. Trihexyphenidyl HCl dosage of 3 to 6 mg daily, in divided doses, is usually adequate.

# Concomitant Use of Trihexyphenidyl HCl with Other Parasympathetic Inhibitors

Trihexyphenidyl HCl may be substituted, in whole or in part, for other parasympathetic inhibitors. The usual technique is partial substitution initially, with progressive reduction in the other medication as the dose of trihexyphenidyl HCl is increased.

The total daily intake of trihexyphenidyl HCl tablets is tolerated best if divided into 3 doses and taken at mealtimes. High doses (>10 mg daily) may be divided into 4 parts, with 3 doses administered at mealtimes and the fourth at bedtime.

# HOW SUPPLIED

Trihexyphenidyl HCl tablets are available as follows:

2 mg – round, flat, scored, white tablets; debossed "5971" above the score and "V" below the score. Available in bottles of 100, 500 and 1000.


5 mg – round, flat, scored, white tablets; debossed "5972" above the score and "V" below the score. Available in bottles of 100, 500, and 1000.

Dispense in a tight, light-resistant container as defined in the USP. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].


Manufactured for: **RICHMOND PHARMACEUTICALS, INC.** Richmond, VA 23233

8182706 Rev 3/08 R0

#### **PRINCIPAL DISPLAY PANEL - 2 mg**



#### **PRINCIPAL DISPLAY PANEL - 5 mg**



# TRIHEXYPHENIDYL HYDROCHLORIDE

trihexyphenidyl hydrochloride tablet

**Product Information** 

**Product Type** 

HUMAN PRESCRIPTION DRUG

Item Code (Source)

NDC:54738-554

Route of Administr	ration	ORAL					
Active Ingredie	nt/Active	e Moiety					
		Ingredient Name			Basis of Str	rength	Strength
<b>TRIHEXYPHENIDYL</b> UNII:6RC5V8B7PO)	HYDROC	HLORIDE (UNII: AO61G8	2577) (TRIHEXYPHENI	DYL -	TRIHEXYPHENIDY HYDROCHLORIDE		2 mg
Inactive Ingred	ients						
		Ingredie	nt Name			S	trength
MAGNESIUM STEAL	RATE (UNI	I: 70097M6I30)					
CELLULOSE, MICR	OCRYSTA	LLINE (UNII: OP1R32D61	U)				
SODIUM STARCH G	LYCOLAT	TE TYPE A POTATO (UN	II: 5856J3G2A2)				
<b>Product Charac</b>	teristics						
Color		WHITE	Score			2 pieces	
Shape		ROUND	Size			8 mm	
Flavor			Imprint Code		5	5971;V	
Contains							
Packaging							
# Item Code		Package Descr	iption	I	Marketing Start Date		ting End ate
1 NDC:54738-554- 01	100 in 1 BO Product	OTTLE, PLASTIC; Type 0:	Not a Combination	12/	24/1998		
2 NDC:54738-554- 02	500 in 1 B Product	OTTLE, PLASTIC; Type 0:	Not a Combination	12/	24/1998		
<b>3</b> NDC:54738-554- 03	1000 in 1 H Product	BOTTLE, PLASTIC; Type (	): Not a Combination	12/	24/1998		
<b>Marketing</b> In	format	ion					
Marketing Catego	ry App	lication Number or Mo	nograph Citation	Mark	eting Start Date	Marketing	g End Date
ANDA		040254		12/24/1	-		

TRIHEXYPHENIDYL H	YDROCHLORIDE		
trihexyphenidyl hydrochloride table	et		
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:54738-555
Route of Administration	ORAL		
Active Ingredient/Active Moi	ety		

Inactive Ingredients				Ingredient N	lame			Basis of St	rength	Strengt
Ingredient Name     Strem       MAGNESIUM STEARATE (UNIE 70097M6130)         CELLULOSE, MICRO CRYSTALLINE (UNIE OPIR32D6 IU)         SODIUM STARCH GLYCOLATE TYPE A POTATO (UNIE 5856J3G2A2)     2        Product Characteristics     2     2        Shape     ROUND     Size     10mm       Flavor     Imprint Code     5972.∨       Contains      Marketing Start     Marketing Start       1     NDC:54738-555-     100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product     12/24/1998     I2/24/1998       2     NDC:54738-555-     1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product     12/24/1998     I2/24/1998       3     NDC:54738-555-     1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product     12/24/1998     I2/24/1998			HYDROC	HLORIDE (UNII:	: AO61G825	77) (TRIHEXYPHENID)				5 mg
Ingredient Name     Strem       MAGNESIUM STEARATE (UNIE 70097M6130)     CELLULOSE, MICRO CRYSTALLINE (UNIE 0P1R32D6 IU)       CELLULOSE, MICRO CRYSTALLINE (UNIE 0P1R32D6 IU)     State of the state of										
AGGNESIUM STEARATE (UNIE 70097M6E0) CELLULO SE, MICRO CRYSTALLINE (UNIE OPIR32D6 IU) SOTIUM STARCH GLYCOLATE TYPE A POTATO (UNIE 5856J3G2A2) Product Characteristics Colv WHITE Score 2 pieces Shape ROUND Size 100m Flavor 010m Flavor 0572, V Contains 0100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 12/24/1998 12/24/1998 100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 12/24/1998 12/24/1998 NDC:54738-555- 1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 12/24/1998 12/24/1998 NDC:54738-555- 1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 12/24/1998 12/24/1998 12/24/1998	In	active Ingred	ients							
CELLUOSE, MICRO CRYSTALLINE (UNIE OPIR32D6 IU SUM STARCH GLYCOLATE TYPE A POTATO (UNIE 5856J3G2A2) SUBUE STARCH GLYCOLATE TYPE				I	ngredient	Name				Strength
SOBIUM STARCH GIVEOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Size 2 jiecs Size 3 jiec 3 jiec FIavor 0 jiec 3 jiec 3 jiec FIavor 0 jiec 3	MA	GNESIUM STEA	RATE (UNI	E:70097M6I30)						
Product Characteristics   VHITE   Score   2 pieces     Shape   ROUND   Size   10mm     Flavor   Gound   Imprint Code   972;V     Total Size     Value   Marketing Start   Marketing Date     Package Description   Marketing Date   Marketing Date     NDC:54738-555-   00 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide     NDC:54738-555-   00 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide     Social Size   100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide     Social Size   100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide     Social Size   100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide     Social Size   100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide     Size   100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998   Guide   Guide <td>CE</td> <td>LLULOSE, MICR</td> <td>OCRYSTA</td> <td>LLINE (UNII: OF</td> <td>P1R32D61U)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	CE	LLULOSE, MICR	OCRYSTA	LLINE (UNII: OF	P1R32D61U)					
VHTEWHTEScore $2  veca$ Imprint Code $3  veca$ <td< td=""><td>so</td><td>DIUM STARCH C</td><td>GLYCOLAT</td><td>ΓΕ ΤΥΡΕ Α ΡΟ Τ</td><td>ATO (UNII:</td><td>5856J3G2A2)</td><td></td><td></td><td></td><td></td></td<>	so	DIUM STARCH C	GLYCOLAT	ΓΕ ΤΥΡΕ Α ΡΟ Τ	ATO (UNII:	5856J3G2A2)				
VHTEWHTEScore $2  veca$ Imprint Code $3  veca$ <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>										
Size   0mm     First	Pr	oduct Charac	teristics							
Imprint Code   572;V     Imprint Code   572;V     Imprint Code   Imprint Code     Impr	Co	lor		WHITE	5	Score		:	2 pieces	
Image: Second state    Image: Second state </td <td>Sh</td> <td>ape</td> <td></td> <td>ROUND</td> <td>5</td> <td>Size</td> <td></td> <td></td> <td colspan="2">10 mm</td>	Sh	ape		ROUND	5	Size			10 mm	
First Start	Fla	vor			]	mprint Code		Į	5972;V	
#Item CodePackage DescriptionMarketing Start DateMarketing Date1NDC:54738-555- 01100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/19982NDC:54738-555- 02500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/19983NDC:54738-555- 031000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/1998	Co	ntains								
#Item CodePackage DescriptionMarketing Start DateMarketing Date1NDC:54738-555- 01100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/19982NDC:54738-555- 02500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/19983NDC:54738-555- 031000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/1998										
#Item CodePackage DescriptionMarketing Start DateMarketing Date1NDC:54738-555- 01100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/19982NDC:54738-555- 02500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/19983NDC:54738-555- 031000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/199812/24/1998	Pa	ckaging								
I01Product12/24/19982NDC:54738-555- 02500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/19983NDC:54738-555- 031000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product12/24/1998		00		Packag	e Descrip	tion	Mark			-
2   02   Product   12/24/1996     3   NDC:54738-555- 03   1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product   12/24/1998						12/24/199	98			
Marketing Information				OTTLE, PLASTIC	C; Type 0: N	ot a Combination	12/24/199	98		
	3 [ (	NDC:54738-555- )3		BOTTLE, PLAST	IC; Type 0:	Not a Combination	12/24/199	98		
	м	arkating In	format	ion						
		•			er or Mono	ograph Citation	Marketing	Start Date	Marketiı	ng End Dat
ANDA ANDA040254 12/24/1998							J			0

Labeler - Richmond Pharmaceuticals, Inc. (043569607)

NameAddressID/FEIBusiness OperationsVintage Pharmaceuticals - Charlottee96832953ANALYSIS(54738-554, 54738-555), MANUFACTURE(54738-554, 54738-555), SANUFACTURE(54738-554, 54738-555)	Establishment			
Vintage Pharmaceuticals - 968329537 ANALYSIS(54738-554, 54738-555), MANUFACTURE(54738-554, 54738-	Name	Address	ID/FEI	Business Operations
Charlotte 555)	Vintage Pharmaceuticals - Charlotte		968329537	ANALYSIS(54738-554, 54738-555) , MANUFACTURE(54738-554, 54738- 555)

Establishment

Name	Address		Business Operations
Vintage Pharmaceuticals- Charlotte		151228897	LABEL(54738-554, 54738-555) , MANUFACTURE(54738-554, 54738-555) , PACK(54738-554, 54738-555)

Name Address ID/I	FEI Business Operations

Richmond Pharmaceuticals, Inc.